Daniel Sidler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9583983/publications.pdf

Version: 2024-02-01

713332 933264 25 630 10 21 citations h-index g-index papers 29 29 29 1256 docs citations all docs times ranked citing authors

#	Article	lF	CITATIONS
1	Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatology, The, 2021, 3, e789-e797.	2.2	179
2	Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B ₁₀₀ â€"Reactive CD4 ⁺ T-Regulatory Cells. Circulation, 2020, 142, 1279-1293.	1.6	100
3	A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. Nature Communications, 2018, 9, 525.	5.8	72
4	TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis. Nature Communications, 2017, 8, 15395.	5.8	50
5	Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. RMD Open, 2022, 8, e002036.	1.8	48
6	LIGHT–HVEM signaling in keratinocytes controls development of dermatitis. Journal of Experimental Medicine, 2018, 215, 415-422.	4.2	32
7	Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study. American Journal of Transplantation, 2021, 21, 2532-2542.	2.6	28
8	Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature. Transplant Infectious Disease, 2021, 23, e13515.	0.7	23
9	The TWEAK/Fn14 pathway is required for calcineurin inhibitor toxicity of the kidneys. American Journal of Transplantation, 2018, 18, 1636-1645.	2.6	22
10	Impact of different urinary tract infection phenotypes within the first year post-transplant on renal allograft outcomes. American Journal of Transplantation, 2022, 22, 1823-1833.	2.6	15
11	Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy. RMD Open, 2022, 8, e002166.	1.8	15
12	Preâ€transplant donorâ€specific HLA antibodies and risk for poor firstâ€year renal transplant outcomes: results from the Swiss Transplant Cohort Study. Transplant International, 2021, 34, 2755-2768.	0.8	9
13	Infection Risk in the First Year After ABO-incompatible Kidney Transplantation: A Nationwide Prospective Cohort Study. Transplantation, 2022, 106, 1875-1883.	0.5	7
14	Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study. Swiss Medical Weekly, 2020, 150, w20354.	0.8	6
15	Outcome of kidney transplantation from very senior donors in Switzerland – a national cohort study. Transplant International, 2021, 34, 689-699.	0.8	5
16	The effect of a previous created distal arteriovenous-fistula on radial bone DXA measurements in prevalent renal transplant recipients. PLoS ONE, 2018, 13, e0200708.	1.1	3
17	Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures. World Journal of Transplantation, 2021, 11, 254-262.	0.6	3
18	Nephrotoxicity of Calcineurin Inhibitors in Kidney Epithelial Cells is Independent of NFAT Signaling. Frontiers in Pharmacology, 2021, 12, 789080.	1.6	3

#	Article	IF	CITATION:
19	Relevance of deceased donor proteinuria for kidney transplantation: a comprehensive national cohort study. Clinical Transplantation, 2022, , e14574.	0.8	2
20	Giant kidneys. Nephrology, 2015, 20, 510-510.	0.7	1
21	Gout tophi on the soles resembling viral warts. Clinical Case Reports (discontinued), 2018, 6, 1121-1123.	0.2	1
22	Distinct Clinical and Laboratory Patterns of Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients. Journal of Fungi (Basel, Switzerland), 2021, 7, 1072.	1.5	1
23	Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply. Lancet Rheumatology, The, 2022, 4, e247-e248.	2.2	O
24	Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney Transplants. Frontiers in Medicine, 2022, 9, 820085.	1.2	0
25	MO193: Capillary Point-Of-Care Creatinine Testing in Kidney Disease Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0